EZH2 inhibitors and uses thereof

By developing new EZH2 inhibitor compounds, the stability and drug resistance issues of existing drugs have been resolved, achieving effective treatment and proliferation inhibition of EZH2-mediated diseases, with excellent inhibitory activity and stability.

CN116457348BActive Publication Date: 2024-11-26NANJING MAISHENG TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202280007243.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-02-26
Filing Date
2022-02-25
Publication Date
2024-11-26
Estimated Expiration
2042-02-25

Smart Images

  • Figure CN116457348B_ABST
    Figure CN116457348B_ABST
Patent Text Reader

Abstract

Disclosed are a compound represented by formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and use thereof in preparing a drug for treating EZH2-mediated diseases. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application belongs to the field of chemical medicine, and specifically relates to an EZH2 inhibitor and its use. Background Art

[0002] Abnormal activity of the core components of polycomb repressive complex 2 (PRC2) (EZH2, EED and SUZ12) is closely related to the occurrence, development and invasion of many diseases, especially malignant tumors. The expression of EZH2, a core component of PRC2, is significantly increased in a variety of malignant tumor tissues such as breast cancer, prostate cancer, colorectal cancer, soft tissue sarcoma, follicular lymphoma, etc. Its overexpression level is positively correlated with the degree of tumor deterioration and poor prognosis. Downregulating the expression of EZH2 by genetic methods can significantly inhibit the proliferation and invasion of tumor cells. At the same time, recurrent somatic mutations of EZH2 have been identified in tumor cells such as diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).

[0003] Tazemetostat is the only EZH2 inhibitor currently approved by the FDA, used to treat soft tissue sarcoma and follicular lymphoma (800 mg / kg BID). At the same time, other redeveloped EZH2 inhibitors are still in the clinical stage, including CPI-1205 (clinical phase I / II), CPI-0209 (clinical phase I), DS-3201 (clinical phase II), SHR-2554 (clinical phase II), etc. Current studies on Tazemetostat have shown that it has problems such as insufficient stability, high dosage, and easy drug resistance. Therefore, the development of EZH2 inhibitors with novel compound structures, good activity and stability is still in urgent need. Summary of the invention

[0004] The present application discloses a class of compounds that can be used as EZH2 inhibitors and their use in preparing drugs for treating EZH2-mediated diseases.

[0005] In one aspect, the present application provides a compound represented by formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof:

[0006]

[0007]

[0008] Among them, R 1 , R 2 , R 3 are each independently selected from hydrogen, halogen, C 1 -C 6 Alkyl, hydroxy, cyano or amino;

[0009] L, U, V, T are each independently selected from C or N, and at least one is N;

[0010] Y is selected from hydrogen, halogen or C 1 -C 6 alkyl;

[0011] X is selected from hydrogen, halogen, C 1 -C 6 Alkyl, alkoxy or -SR 4 , R 4 C 1 -C 6 alkyl;

[0012] Z is for C 3 -C 7 Cycloalkyl or 4 to 7 membered heterocyclic group, each of which is optionally substituted by 1 to 3 selected from halogen, C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, halogenated C 1 -C 6 Alkoxy or -NRaRb group substitution;

[0013] Ra is hydrogen, C 1 -C 6 Alkyl or halogenated C 1 -C 6 alkyl;

[0014] Rb is C 1 -C 6 Alkyl, halogenated C 1 -C 6 alkyl or a 4 to 7 membered heterocyclic group, wherein the heterocyclic group is optionally substituted by 1 to 3 members selected from halogen, C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy or halogenated C 1 -C 6 Alkoxy group substitution;

[0015] or Ra and Rb together with the nitrogen atom to which they are attached form a radical optionally substituted by 1 to 3 atoms selected from halogen, C 1 -C 6 Alkyl, halogenated C 1 -C 6 a 4- to 7-membered heterocyclic group substituted with an alkyl group or an -ORc group;

[0016] Rc is C1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl or C 3 -C 7 Cycloalkyl;

[0017] m, n' are each independently 0, 1 or 2;

[0018] n is 0, 1, 2, 3 or 4; and

[0019] Represents a single bond or a double bond.

[0020] In certain embodiments, Formula (I) is Formula (Ia):

[0021]

[0022] Among them, R 1 , R 2 , R 3 are each independently selected from hydrogen, halogen, C 1 -C 6 Alkyl, hydroxy, cyano or amino;

[0023] L, U, V, T are each independently selected from C or N, and at least one is N;

[0024] Y is selected from hydrogen, halogen or C 1 -C 6 alkyl;

[0025] X is selected from hydrogen, halogen, C 1 -C 6 Alkyl, alkoxy or -SR 4 , R 4 C 1 -C 6 alkyl;

[0026] m, n' are each independently 0, 1 or 2;

[0027] n is 0, 1, 2, 3 or 4; and

[0028] Represents a single bond or a double bond.

[0029] In certain embodiments, Formula (I) is Formula (Ib):

[0030]

[0031] Among them, R 1 , R 2 , R 3 are each independently selected from hydrogen, halogen, C 1-C 6 Alkyl, hydroxy, cyano or amino;

[0032] U and V are each independently selected from C or N;

[0033] X is selected from hydrogen, halogen, C 1 -C 6 Alkyl, alkoxy or -SR 4 , R 4 C 1 -C 6 alkyl;

[0034] m, n' are each independently 0, 1 or 2;

[0035] n is 0, 1, 2, 3 or 4; and

[0036] Represents a single bond or a double bond.

[0037] In certain embodiments, Formula (I) is Formula (Ic):

[0038]

[0039] Among them, R 1 , R 2 , R 3 are each independently selected from hydrogen, halogen, C 1 -C 6 Alkyl, hydroxy, cyano or amino;

[0040] U and V are each independently selected from C or N;

[0041] X is selected from hydrogen, halogen, C 1 -C 6 Alkyl, alkoxy or -SR 4 , R 4 C 1 -C 6 alkyl;

[0042] m, n' are each independently 0, 1 or 2;

[0043] n is 0, 1, 2, 3 or 4; and

[0044] Represents a single bond or a double bond.

[0045] In certain embodiments, the compound represented by formula (I) is selected from:

[0046]

[0047]

[0048] On the other hand, the present application provides a pharmaceutical composition comprising a therapeutically effective amount of the aforementioned compound, or a pharmaceutically acceptable salt, ester, prodrug, complex, solvate, hydrate or isomer thereof; and a pharmaceutically acceptable carrier or excipient.

[0049] On the other hand, the present application provides the use of the aforementioned compound, or a pharmaceutically acceptable salt, ester, prodrug, complex, solvate, hydrate or isomer thereof for preparing a drug for treating an EZH2-mediated disease.

[0050] In certain embodiments, the disease is cancer.

[0051] In certain embodiments, the cancer is lung cancer, gastric cancer, liver cancer, breast cancer, nasopharyngeal cancer, pancreatic cancer, ovarian cancer, cervical cancer, colorectal cancer, glioma, melanoma, prostate cancer, kidney cancer, esophageal cancer, mesothelioma, head and neck cancer, bladder cancer, salivary gland cancer, leukemia, or lymphoma.

[0052] On the other hand, the present application provides a compound represented by formula (II) or a stereoisomer thereof:

[0053]

[0054] Among them, R 1 , R 2 , R 3 、U、V、m、n、n'、 As defined above, they can be used to prepare the aforementioned compounds.

[0055] the term:

[0056] Unless stated otherwise, the terms used in the specification and claims have the following meanings.

[0057] The term "isomer" includes enantiomeric, diastereomeric, and geometric (or conformational) isomeric forms of a given structure. For example, the present application includes R and S configurations for each asymmetric center, Z and E double bond isomers, Z and E conformational isomers, single stereochemical isomers and enantiomers, diastereomers, and geometric (or conformational) isomer mixtures.

[0058] The term "pharmaceutically acceptable salt" refers to, for example, acid addition salts and / or base salts thereof. Suitable acid addition salts are formed from acids, which form non-toxic salts, such as hydrochlorides / chlorides. Suitable base salts are formed from bases, which form non-toxic salts, such as calcium and sodium salts. Hemi-salts of acids and bases, such as hemisulphate and hemicalcium salts, can also be formed.

[0059] The term "therapeutically effective amount" refers to an amount of a compound of the present application that (i) treats a specific disease, condition or disorder; (ii) alleviates, relieves or eliminates one or more symptoms of a specific disease, condition or disorder; or (iii) prevents or delays the onset of one or more symptoms of a specific disease, condition or disorder described herein.

[0060] The term "pharmaceutically acceptable carrier or excipient" refers to a non-toxic carrier, adjuvant or vehicle that does not destroy the pharmacological activity of the compound formulated therewith.

[0061] The term "alkyl" refers to a saturated aliphatic hydrocarbon group, which is a straight or branched chain group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 12 carbon atoms, and more preferably an alkyl group containing 1 to 6 carbon atoms. Non-limiting examples of lower alkyl groups containing 1 to 6 carbon atoms include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, and the like.

[0062] The term "alkenyl" refers to an aliphatic hydrocarbon having at least one carbon-carbon double bond, including straight and branched chains having at least one carbon-carbon double bond. In some embodiments, the alkenyl group has 2 to 20 carbon atoms, 2 to 10 carbon atoms, 2 to 6 carbon atoms, 3 to 6 carbon atoms, or 2 to 4 carbon atoms. For example, the term "C 2-6 The term "alkenyl" refers to straight or branched unsaturated groups of 2 to 6 carbon atoms (having at least one carbon-carbon double bond), including but not limited to vinyl, 1-propenyl, 2-propenyl (allyl), isopropenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, and the like.

[0063] The term "alkynyl" refers to an aliphatic hydrocarbon having at least one carbon-carbon triple bond, including straight and branched chains having at least one carbon-carbon triple bond. In some embodiments, the alkynyl group has 2 to 20 carbon atoms, 2 to 10 carbon atoms, 2 to 6 carbon atoms, or 3 to 6 carbon atoms. For example, "C 2-6 "Alkynyl" includes straight or branched chain unsaturated groups (having at least one carbon-carbon triple bond) of 2 to 6 carbon atoms.

[0064] The term "alkoxy" refers to -O-(alkyl) and -O-(unsubstituted cycloalkyl), wherein alkyl is as defined above. Non-limiting examples of alkoxy include: methoxy, ethoxy, propoxy, butoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy.

[0065] The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, wherein the cycloalkyl ring contains 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, more preferably 3 to 6 carbon atoms (e.g., 3, 4, 5 or 6 carbon atoms), and most preferably 5 to 6 carbon atoms. Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, etc.; polycyclic cycloalkyls include cycloalkyls of spirocyclic, condensed and bridged rings.

[0066] The term "spirocycloalkyl" refers to a polycyclic group that shares a carbon atom (called spiral atom) between 5 to 20 monocyclic rings, which may contain one or more double bonds, but each ring does not have a completely conjugated π electron system. Preferably, it is 6 to 14 yuan, more preferably 7 to 10 yuan (e.g., 7, 8, 9 or 10 yuan). According to the number of spiral atoms shared between rings, the spirocycloalkyl is divided into a single spiral cycloalkyl, a double spiral cycloalkyl or a multi-spirocycloalkyl, preferably a single spiral cycloalkyl and a double spiral cycloalkyl, more preferably a 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 5 yuan or a 5 yuan / 6 yuan single spiral cycloalkyl.

[0067] The term "condensed cycloalkyl" refers to a 5 to 20-membered, all-carbon polycyclic group in which each ring in the system shares a pair of adjacent carbon atoms with other rings in the system, wherein one or more rings may contain one or more double bonds, but each ring does not have a completely conjugated π electron system. Preferably, it is 6 to 14 members, more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into a bicyclic, tricyclic, tetracyclic or polycyclic condensed cycloalkyl, preferably a bicyclic or tricyclic, more preferably a 5-membered / 5-membered or 5-membered / 6-membered bicyclic alkyl.

[0068] The term "bridged cycloalkyl" refers to a 5-20-membered, all-carbon polycyclic group in which any two rings share two carbon atoms that are not directly connected, which may contain one or more double bonds, but each ring does not have a completely conjugated π electron system. It is preferably 6-14 members, and more preferably 7-10 members. According to the number of constituent rings, it can be divided into a bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl, preferably a bicyclic, tricyclic or tetracyclic, and more preferably a bicyclic or tricyclic.

[0069] The term "heterocyclyl" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent containing 3 to 20 ring atoms, one or more of which is a heteroatom selected from nitrogen, oxygen or S(O)m (wherein m is an integer from 0 to 2), but excluding the ring part of -OO-, -OS- or -SS-, and the remaining ring atoms are carbon. Preferably, it contains 3 to 12 ring atoms, of which 1 to 4 are heteroatoms; more preferably, it contains 3 to 8 ring atoms, of which 1 to 3 are heteroatoms; most preferably, it contains 5 to 6 ring atoms, of which 1 to 2 or 1 to 3 are heteroatoms. Non-limiting examples of monocyclic heterocyclyls include pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothienyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, etc., preferably tetrahydropyranyl, piperidinyl, pyrrolidinyl. Polycyclic heterocyclyls include spiro heterocyclyls, fused heterocyclyls and bridged heterocyclyls.

[0070] The term "spiro heterocyclic group" refers to a polycyclic heterocyclic group in which one atom (called a spiro atom) is shared between 5 to 20 monocyclic rings, wherein one or more ring atoms are heteroatoms selected from nitrogen, oxygen or S(O)m (wherein m is an integer from 0 to 2), and the remaining ring atoms are carbon. It may contain one or more double bonds, but each ring does not have a completely conjugated π electron system. It is preferably 6 to 14 yuan, more preferably 7 to 10 yuan. According to the number of shared spiro atoms between rings, the spiro heterocyclic group is divided into a single spiro heterocyclic group, a double spiro heterocyclic group or a multi-spiro heterocyclic group, preferably a single spiro heterocyclic group and a double spiro heterocyclic group, more preferably a 4-yuan / 4-yuan, 4-yuan / 5-yuan, 4-yuan / 6-yuan, 5-yuan / 5-yuan or 5-yuan / 6-yuan single spiro heterocyclic group.

[0071] The term "fused heterocyclic group" refers to a polycyclic heterocyclic group of 5 to 20 members, each ring in the system shares a pair of atoms adjacent to other rings in the system, one or more rings may contain one or more double bonds, but each ring does not have a completely conjugated π electron system, wherein one or more ring atoms are heteroatoms selected from nitrogen, oxygen or S(O)m (wherein m is an integer from 0 to 2), and the remaining ring atoms are carbon. Preferably, it is 6 to 14 members, more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into a bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic group, preferably a bicyclic or tricyclic group, more preferably a 5-membered / 5-membered or 5-membered / 6-membered bicyclic fused heterocyclic group.

[0072] The term "bridged heterocyclic group" refers to a polycyclic heterocyclic group of 5 to 14 members, any two rings sharing two atoms that are not directly connected, which may contain one or more double bonds, but each ring does not have a completely conjugated π electron system, wherein one or more ring atoms are heteroatoms selected from nitrogen, oxygen or S(O)m (wherein m is an integer from 0 to 2), and the remaining ring atoms are carbon. Preferably, it is 6 to 14 members, more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into a bicyclic, tricyclic, tetracyclic or polycyclic bridged heterocyclic group, preferably a bicyclic, tricyclic or tetracyclic, more preferably a bicyclic or tricyclic.

[0073] The heterocyclic group includes the heterocyclic group as described above (including monocyclic, spiro heterocyclic, fused heterocyclic and bridged heterocyclic) fused to an aryl, heteroaryl or cycloalkyl ring, wherein the ring connected to the parent structure is a heterocyclic group, and non-limiting examples thereof include:

[0074]

[0075] The term "aryl" refers to a 6- to 14-membered all-carbon monocyclic or fused polycyclic (ie, rings which share adjacent pairs of carbon atoms) group having a conjugated π electron system, preferably 6- to 10-membered, such as phenyl and naphthyl.

[0076] The term "heteroaryl" refers to a heteroaromatic system containing 1 to 4 heteroatoms and 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur and nitrogen. The heteroaryl group is preferably 5 to 10-membered, containing 1 to 3 heteroatoms; more preferably 5 or 6-membered, containing 1 to 2 heteroatoms; preferably, for example, imidazolyl, furanyl, thienyl, thiazolyl, pyrazolyl, oxazolyl, pyrrolyl, tetrazolyl, pyridyl, pyrimidinyl, thiadiazole, pyrazinyl and pyridazinyl.

[0077] The heteroaryl group includes a heteroaryl group as described above fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring connected to the parent structure is a heteroaryl ring, and non-limiting examples thereof include:

[0078]

[0079] The term "hydroxyalkyl" refers to an alkyl group substituted with a hydroxy group, wherein alkyl is as defined above.

[0080] The term "haloalkyl" refers to an alkyl group substituted with one or more halogens, wherein alkyl is as defined above.

[0081] The term "haloalkoxy" refers to an alkoxy group substituted with one or more halogens, wherein alkoxy is as defined above.

[0082] The term "deuterated alkyl" refers to an alkyl group substituted with one or more deuterium atoms, wherein alkyl is as defined above.

[0083] The term "deuterated alkoxy" refers to an alkoxy group substituted with one or more deuterium atoms, wherein alkoxy is as defined above.

[0084] The term "cycloalkylalkyl" refers to an alkyl group substituted with one or more cycloalkyl groups, wherein cycloalkyl and alkyl are as defined above.

[0085] The term "cycloalkyloxy" refers to an -O-cycloalkyl group, wherein cycloalkyl is as defined above.

[0086] The term "heterocyclylalkyl" refers to an alkyl group substituted with one or more heterocyclyl groups, wherein heterocyclyl and alkyl are as defined above.

[0087] The term "arylalkyl" refers to an alkyl group substituted with one or more aryl groups, wherein aryl and alkyl are as defined above.

[0088] The term "hydroxy" refers to an -OH group.

[0089] The term "halogen" refers to fluorine, chlorine, bromine or iodine.

[0090] The term "amino" refers to -NH 2 .

[0091] The term "cyano" refers to -CN.

[0092] The term "nitro" refers to -NO 2 .

[0093] The term "carboxy" refers to -C(O)OH. DETAILED DESCRIPTION

[0094] Example 1: Synthesis of 10-((1r,4r)-4-(dimethylamino)cyclohexyl)-8,10-dimethyl-6-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5,6-dihydro-[1,4]diazepine[6,7,1-hi][1,3]dioxazolo[4,5-e]indol-7(4H)-one

[0095]

[0096] In an ice-water bath, methyl 3,4-dihydroxy-2-methylbenzoate (20.00 g, 0.11 mol, 1.0 eq.), dichloromethane (DCM, 100 mL) and acetic acid (10 mL) were added to the reaction flask, and then bromine (17.57 g, 0.11 mol, 1.0 eq.) was added dropwise, and the mixture was naturally warmed to room temperature and reacted overnight for 12 h. The reaction solution was spin-dried, and water (100 mL) was added to slurry and filtered. The filter cake was slurried with dichloromethane (20 mL) and filtered again. The filter cake was pumped dry with an oil pump to obtain intermediate 1.1 (24.60 g, 85.9% yield). MS: [M+H] +=261.

[0097] Intermediate 1.1 (24.60 g, 0.094 mol, 1.0 eq.) was dissolved in toluene (250 mL). tert-butyl trans-N-(4-ethynylcyclohexyl)carbamate (25.00 g, 0.11 mol, 1.2 eq.), Ru 3 (CO) 12 (1.81 g, 0.003 mol, 0.03 eq.), replaced with nitrogen three times and heated to 105°C. After overnight reaction for 10 h, tert-butyl trans-N-(4-ethynylcyclohexyl)carbamate (25.00 g, 0.11 mol, 1.2 eq.) and Ru were added. 3 (CO) 12 (1.81 g, 0.003 mol, 0.03 eq.), nitrogen was pumped three times and then heated to 105 ° C, and the reaction was continued for 10 h. After the reaction solution was cooled to room temperature, it was filtered with diatomaceous earth. The filtrate was concentrated and purified by column chromatography (PE: EA) = 10: 1 to obtain intermediate 1.2 (36.70 g, 80.4% yield). MS: [M+H] + =485.

[0098] Add intermediate 1.2 (36.70 g, 0.076 mol, 1.0 eq.) to the reaction flask, add acetic anhydride (120 mL) to dissolve, and drop 1 drop of concentrated sulfuric acid. Add dilute nitric acid (110 mL) dropwise under ice-salt bath conditions. Control the internal temperature not to exceed 45°C. After the addition is complete, react at room temperature for 1 hour. Pour the reaction solution into ice-cold 30% sodium hydroxide aqueous solution (500 mL), extract twice with ethyl acetate, wash the organic phase with saturated brine, and use MgSO 4 After drying and spin drying, intermediate 1.3 (32.60 g, 100% yield) was obtained, which was directly used for the next step reaction.

[0099] Dissolve the intermediate 1.3 (32.60 g, 0.076 mol, 1.0 eq.) in DCM, add triethylamine (23.00 g, 0.23 mol, 3.0 eq.) and DMAP (0.93 g, 0.0076 mol, 0.1 eq.). Add di-tert-butyl dicarbonate (24.80 g, 0.11 mol, 1.5 eq.) under ice bath conditions. Transfer the reaction to room temperature and react for 2 h. After concentrating the reaction solution, separate and purify it by column chromatography (PE:EA=4:1) to obtain intermediate 1.4 (22.89 g, 56.9% yield). MS: [M+H] + =530.

[0100] Diisopropylamine (200 mL) and tetrahydrofuran (20 mL) were added to a reaction bottle containing intermediate 1.4 (2.20 g, 0.0043 mol, 1.0 eq.). After stirring and dissolving, CuI (7.74 mg, 0.043 mmol, 0.01 eq.), TMSA (1.57 g, 0.0086 mol, 2 eq.) and Pd(PPh 3 ) 2 Cl 2 (0.090 g, 0.13 mmol, 0.03 eq.). After nitrogen replacement three times, the temperature was raised to 70 ° C and the reaction was continued for 6 h. The reaction solution was filtered through diatomaceous earth. After the reaction solution was dried, it was separated and purified by column chromatography (PE: EA = 4: 1) to obtain intermediate 1.5 (1.89 g, 80.3% yield) as a dark brown oil. MS: [M+H] + =547.

[0101] Add TBAF tetrahydrofuran solution (1M, 10 mL) to the reaction bottle containing intermediate 1.5 (1.89 g, 0.035 mol, 1.0 eq.) and stir at room temperature for 1 h. After the reaction solution was spin-dried, water was added, extracted twice with ethyl acetate, washed with saturated sodium chloride aqueous solution and dried over anhydrous magnesium sulfate. Separate and purify by column chromatography (PE:EA=4:1) to obtain intermediate 1.6 (1.49 g, 90.9% yield). MS: [M+H] + =475.

[0102] DCM (15 mL) and DMF (15 mL) were added to the reaction bottle containing intermediate 1.6 (1.49 g, 0.003 mol, 1.0 eq.). After stirring and dissolving, stannous chloride dihydrate (3.56 g, 0.150 mol, 5.0 eq.) was added. Stir at room temperature for 2 h. Saturated sodium bicarbonate aqueous solution (2 L) was added to the reaction solution. Extracted twice with ethyl acetate, washed with saturated sodium chloride aqueous solution, MgSO 4 Dry. Spin dry and purify by column chromatography (PE:EA=4:1) to obtain intermediate 1.7 (0.89 g, 63.9% yield). MS: [M+H] + =445.

[0103] To a reaction flask containing intermediate 1.7 (0.89 g, 0.002 mol, 1.0 eq.), pyridine (10 mL), Cp(PPh 3 ) 2 RuCl (0.15 g, 0.003 mol, 0.1 eq.). After nitrogen replacement three times, the temperature was raised to 90°C for reaction for 2 h. The reaction solution was filtered through diatomaceous earth. It was separated and purified by column chromatography (PE:EA=4:1) to obtain intermediate 1.8 (0.81 g, 90.6% yield). MS: [M+H]+ =445. 1 H NMR (400 MHz, DMSO-d 6 )δ10.91(s,1H),7.30-7.24(m,1H),6.75(d,J=7.9Hz,1H),6.37-6.34(m,1H),3.87(s,3H),3. 25-3.10(m,1H),2.48(s,3H),1.93-1.74(m,5H),1.59(s,3H),1.36(s,9H),1.30-1.06(m,4H).

[0104] Add DMF (50 mL) to the reaction bottle containing intermediate 1.8 (0.81 g, 0.0018 mol, 1.0 eq.), stir, lower the temperature to 0 ° C, slowly add NaH (0.087 g, 0.0022 mol, 1.2 eq.), react for 0.5 h, add 1,2,3-oxathiozolidine-3-carboxylic acid tert-butyl ester 2,2-dioxide (0.81 g, 0.0036 mol, 2.0 eq.). Naturally warm to room temperature and react for 6 h. Add water to the reaction solution, extract twice with ethyl acetate, wash the organic phase with saturated sodium chloride aqueous solution, MgSO 4 Dry. Spin dry to obtain intermediate 1.9 (0.62 g, 58.1% yield). MS: [M+H] + =588.

[0105] Add methanol (12 mL) to the reaction bottle containing intermediate 1.9 (0.62 g, 0.001 mol, 1.0 eq.), then add hydrochloric acid 1,4-dioxane solution (4 M, 3 mL), heat to 70 ° C, and react for 0.5 h. After the reaction liquid is dried, intermediate 1.10 is obtained, which is directly used in the next step reaction.

[0106] Add methanol (10 mL) to the reaction bottle containing intermediate 1.10, stir to dissolve, add cesium carbonate (0.98 g, 0.003 mol, 3.0 eq.), heat to 70°C, and react for 2 h. The reaction liquid is spin-dried to obtain intermediate 1.11, which is directly used in the next step.

[0107] Add DCM (10 mL) to the reaction bottle containing intermediate 1.11, stir and dissolve, add triethylamine (0.30 g, 0.003 mol, 3.0 eq.), add di-tert-butyl dicarbonate (0.33 g, 0.0015 mol, 1.5 eq.) under ice-water bath. Transfer to room temperature and react for 1 h. After the reaction liquid is spin-dried, it is separated and purified by column chromatography (DCM: MeOH = 20: 1) to obtain intermediate 1.12 (0.29 g, 61.5% yield). MS: [M+H] + =456.

[0108] DMF (5 mL) was added to the reaction bottle containing intermediate 1.12 (0.29 g, 0.60 mmol, 1.0 eq.), stirred, and t-BuOK (0.14 g, 12.0 mol, 2.0 eq.) was added under ice-water bath conditions. After stirring for 20 min, 2-(benzyloxy)-3-(chloromethyl)-6-methyl-4-(methylthio)pyridine (0.2 g, 0.72 mmol, 1.2 eq.) was added. After reacting for 3 h, water (50 mL) was added to the reaction solution, and then extracted with ethyl acetate (50 mL×3). Washed with saturated sodium chloride aqueous solution, MgSO 4 After drying, the product was separated and purified by column chromatography (PE:EA=4:1) to obtain intermediate 1.13 (0.39 g, 90.4% yield). MS: [M+H] + =713.

[0109] Intermediate 1.13 (0.39 g, 5.4 mmol, 1.0 eq.) was dissolved in 5 mL of methanol, and 1,4-dioxane hydrochloride (1 mL, 7 M) was added, and the temperature was raised to 70°C for 0.5 h. The reaction solution was dried to obtain intermediate 1.14 (0.28 g, 100% yield).

[0110] The intermediate 1.14 (0.28 g, 5.4 mmol, 1.0 eq.) was dissolved in 5 mL of methanol, and a formaldehyde aqueous solution (0.5 mL, 37%, 10 eq.) was added. After stirring for 15 min, STAB (0.57 g, 2.7 mmol, 5 eq.) was added and stirred for another 15 min. The reaction solution was then spin-dried and purified by column chromatography (DCM: MeOH = 8: 1) to obtain the title compound of Example 1 (0.28 g, 94.3% yield). MS: [M+H] + =551. 1 H NMR (400 MHz, DMSO-d 6 )11.70(s,1H),7.21(s,1H),6.30(s,1H),6.14(s,1H),4.73(s,2H),4.07(s,2H),3.51(s,2H),2.65(s,3H),2. 41(d,J=7.7Hz,6H),2.32-2.36(m,1H),2.30(s,3H),2.21(s,3H),1.89(s,5H),1.59(s,3H),1.19-1.28(m,4H).

[0111] Example 2: 8-Chloro-10-((1r, 4r)-4-(dimethylamino)cyclohexyl)-10-methyl-6-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5,6-dihydro-[1,4]diazepine[6,7,1-hi][1,3]dioxa[4,5-e]indol-7(4H)-one

[0112]

[0113] In an ice-water bath, methyl 3,4-dihydroxy-2-chlorobenzoate (20 g, 0.10 mol, 1.0 eq.), dichloromethane (100 mL) and acetic acid (10 mL) were added to the reaction flask, and then liquid bromine (17.50 g, 0.1 mol, 1.1 eq.) was added dropwise, and the mixture was naturally warmed to room temperature and reacted overnight for 12 h. The reaction solution was spin-dried, and water (100 mL) was added to slurry and filtered. The filter cake was slurried with dichloromethane (20 mL) and filtered again. The filter cake was pumped dry with an oil pump to obtain intermediate 2.1 (24.00 g, 85.7% yield). MS: [M+H] + =280. 1 HNMR (400MHz, DMSO), 7.35 (d, J = 3.3Hz, 1H), 3.70 (s, 3H).

[0114] Intermediate 2.1 (24.00 g, 0.085 mol, 1.0 eq.) was dissolved in toluene (200 mL). tert-butyl trans-N-(4-ethynylcyclohexyl)carbamate (20.00 g, 0.88 mol, 0.88.00 eq.), Ru 3 (CO) 12 (1.60g, 0.00255mol, 0.03eq.), nitrogen was replaced 3 times and then heated to 105°C. After overnight reaction for 10h, trans-N-(4-ethynylcyclohexyl)carbamic acid tert-butyl ester (20.00g, 0.88mol, 0.88eq.) was added. Nitrogen was pumped 3 times and then heated to 105°C. The reaction was continued for another 10h. After the reaction solution was cooled to room temperature, it was filtered with diatomaceous earth. After concentration, it was separated and purified by column chromatography (PE:EA) = 10:1 to obtain intermediate 2.2 (24.00g, 56.6% yield). MS: [M+H] + =504.

[0115] Add intermediate 2.2 (24.00 g, 0.047 mol, 1.0 eq.) to the reaction flask, add acetic anhydride (120 mL) to dissolve, and add 1 drop of concentrated sulfuric acid. Add dilute nitric acid (60 mL) dropwise under ice-salt bath conditions. Control the internal temperature not to exceed 45°C. After the addition is complete, react at room temperature for 1 hour. Pour the reaction solution into ice-cold 30% sodium hydroxide aqueous solution (300 mL), extract twice with ethyl acetate, wash the organic phase with saturated brine, and MgSO 4 After drying and spin drying, intermediate 2.3 (21.30 g, 100% yield) was obtained, which was directly used for the next step reaction.

[0116] Dissolve intermediate 2.3 (21.30 g, 0.047 mol, 1.0 eq.) in DCM, add triethylamine (15.00 g, 0.15 mol, 3.0 eq.), DMAP (0.57 g, 0.0047 mol, 0.1 eq.). Add di-tert-butyl dicarbonate (17.50 g, 0.64 mol, 1.5 eq.) under ice bath conditions. Transfer to room temperature and react for 2 h. After concentrating the reaction solution, separate and purify by column chromatography (PE:EA=4:1) to obtain intermediate 2.4 (20.80 g, 75.0% yield). MS: [M+H] + =549. 1 H NMR(400MHz,DMSO),7.51(s,1H),6.75(d,J=3.3Hz,1H),3.80(s,3H),3.21-3 .05(m,1H),1.95-1.65(m,5H),1.70(s,3H),1.45(s,9H),1.30-1.15(m,4H).

[0117] Diisopropylamine (20 mL) and tetrahydrofuran (5 mL) were added to a reaction bottle containing intermediate 2.4 (2.00 g, 3.80 mmol, 1.0 eq.). After stirring and dissolving, CuI (7.10 mg, 0.038 mmol, 0.01 eq.), TMSA (1.38 g, 7.6 mol, 2 eq.), Pd(PPh 3 ) 2 Cl 2 (83.60 mg, 0.11 mmol, 0.03 eq.). After nitrogen replacement three times, the temperature was raised to 70°C and the reaction was continued for 6 h. The reaction solution was filtered through diatomaceous earth. After the reaction solution was dried, it was separated and purified by column chromatography (PE:EA=4:1) to obtain intermediate 2.5 (1.89 g, 80.3% yield) as a dark brown oil. MS: [M+H] + =567.

[0118] Add TBAF tetrahydrofuran solution (1M, 10mL) to the reaction bottle containing intermediate 2.5 (1.89g, 3.30mmol, 1.0eq.) and stir at room temperature for 1h. After the reaction solution was spin-dried, water was added, extracted twice with ethyl acetate, washed with saturated sodium chloride aqueous solution and dried over anhydrous magnesium sulfate. Separate and purify by column chromatography (PE:EA=4:1) to obtain intermediate 2.6 (1.49g, 90.3% yield) as a dark brown oil. MS: [M+H] + =495.

[0119] DCM (15 mL) and DMF (15 mL) were added to the reaction bottle containing intermediate 2.6 (1.49 g, 0.0030 mmol, 1.0 eq.). After stirring and dissolving, stannous chloride dihydrate (3.38 g, 0.0150 mmol, 5.0 eq.) was added and stirred at room temperature for 2 h. Saturated sodium bicarbonate aqueous solution (2 L) was added to the reaction solution. The mixture was extracted with ethyl acetate twice, washed with saturated sodium chloride aqueous solution, and MgSO 4 Dry. Spin dry and purify by column chromatography (PE:EA=4:1) to obtain intermediate 2.7 (1.10 g, 78.6% yield). MS: [M+H] + =465.

[0120] To a reaction flask containing intermediate 2.7 (1.10 g, 0.0023 mol, 1.0 eq.), pyridine (50 mL), Cp(PPh 3 ) 2 RuCl (0.15 g, 0.00023 mol, 0.1 eq.). After nitrogen replacement three times, the temperature was raised to 90°C for reaction for 2 h. The reaction solution was filtered through diatomaceous earth. It was separated and purified by column chromatography (PE:EA=4:1) to obtain intermediate 1.8 (1.00 g, 90.9% yield). MS: [M+H] + =465.

[0121] Add DMF (20 mL) to the reaction bottle containing intermediate 2.8 (1.00 g, 0.0022 mol, 1.0 eq.). Stir and lower the temperature to 0 ° C. Slowly add NaH (0.10 g, 0.0026 mol, 1.2 eq.). After 0.5 h, add 1,2,3-oxathiozolidine-3-carboxylic acid tert-butyl ester 2,2-dioxide (1.46 g, 0.0044 mol, 2.0 eq.). Naturally warm to room temperature and react for 6 h. Add water to the reaction solution, extract twice with ethyl acetate, wash the organic phase with saturated sodium chloride aqueous solution, MgSO 4 Drying. Spin drying gave intermediate 2.9 (0.95 g, 73.0% yield). MS: [M+H] + =608.

[0122] Add methanol (12 mL) to the reaction bottle containing intermediate 2.9 (0.95 g, 0.0015 mol, 1.0 eq.), then add hydrochloric acid 1,4-dioxane solution (4 M, 3 mL), heat to 70 ° C, and react for 0.5 h. After the reaction liquid is dried, intermediate 2.10 is obtained, which is directly used in the next step reaction.

[0123] Add methanol (10 mL) to the reaction bottle containing intermediate 2.10, stir to dissolve, add cesium carbonate (1.38 g, 0.0045 mol, 3.0 eq.), heat to 70°C, and react for 2 h. The reaction liquid was spin-dried to obtain intermediate 2.11, which was directly used in the next step.

[0124] Add DCM (60 mL) to the reaction bottle containing intermediate 2.11, stir and dissolve, add triethylamine (0.58 g, 0.0045 mol, 3.0 eq.), add di-tert-butyl dicarbonate (0.49 g, 0.0225 mol, 1.5 eq.) under ice-water bath. Transfer to room temperature and react for 1 h. After the reaction liquid is spin-dried, it is separated and purified by column chromatography (DCM: MeOH = 20: 1) to obtain intermediate 2.12 (0.51 g, 71.4% yield). MS: [M+H] + =476.

[0125] DMF (30 mL) was added to the reaction bottle containing intermediate 2.12 (0.51 g, 0.001 mol, 1.0 eq.), and the mixture was stirred. t-BuOK (0.22 g, 0.002 mol, 2.0 eq.) was added under ice-water bath conditions. After stirring for 20 min, 2-(benzyloxy)-3-(chloromethyl)-6-methyl-4-(methylthio)pyridine (0.32 g, 0.0012 mol, 1.2 eq.) was added. After reacting for 3 h, water (200 mL) was added to the reaction solution, and then extracted with ethyl acetate (80 mL × 3). The mixture was washed with saturated sodium chloride aqueous solution and MgSO 4 After drying, the product was separated and purified by column chromatography (PE:EA=4:1) to obtain intermediate 2.13 (0.65 g, 91.5% yield) as a yellow solid. MS: [M+H] + =733.

[0126] Intermediate 2.13 (0.65 g, 0.89 mmol, 1.0 eq.) was dissolved in 5 mL of methanol, and 1,4-dioxane hydrochloride (0.5 mL, 7 M) was added, and the temperature was raised to 70°C for 0.5 h. The reaction solution was dried to obtain intermediate 2.14 (0.56 g, 100% yield).

[0127] The intermediate 2.14 (0.56 g, 0.89 mmol, 1.0 eq.) was dissolved in 50 mL of methanol, and a formaldehyde aqueous solution (1.0 mL, 37%, 10 eq.) was added. After stirring for 15 min, STAB (0.95 g, 4.45 mmol, 5 eq.) was added and stirred for another 15 min. The reaction solution was then spin-dried and purified by column chromatography (DCM: MeOH = 8: 1) to obtain the title compound of Example 2 (0.28 g, 48.3% yield). MS: [M+H] + =571. 1 H NMR (400MHz, DMSO) δ11.73 (s, 1H), 7.35 (d, J = 3.3Hz, 1H), 6.38 (d, J = 3.3Hz, 1H),6.15(s,1H),4.73(d,J=17.8Hz,2H),4.23(d,J=6.5Hz,2H),3.55(s,2H) ,2.63(s,3H),2.43(s,3H),2.49(s,3H),2.30-2.36(m,1H),2.22(s,3H),1.9 5-2.05(m,4H),1.65(d,J=6.4Hz,3H),1.48-1.55(m,1H),1.25-1.40(m,4H).

[0128] Example 3: Synthesis of 10-((1r,4r)-4-(dimethylamino)cyclohexyl)-8,10-dimethyl-6-((6-methyl-4-(methylthio)-2-oxo-2,3-dihydropyridin-3-yl)methyl)-5,6-dihydro-[1,4]diazepine[6,7,1-hi][1,3]dioxa[4,5-e]indazol-7(4H)-one

[0129]

[0130] Methyl 3,4-dihydroxy-2,5-dimethylbenzoate (10.0 g, 51.48 mmol, 1.0 eq.) was dissolved in toluene (150 mL). tert-butyl trans-N-(4-ethynylcyclohexyl)carbamate (11.50 g, 51.47 mmol, 1.0 eq.) and Ru were added under stirring. 3 (CO) 12 (0.64 g, 1.54 mmol, 0.03 eq.), replaced with nitrogen three times and heated to 105 ° C. After overnight reaction for 10 h, tert-butyl trans-N-(4-ethynylcyclohexyl)carbamate (11.50 g, 51.48 mmol, 1.2 eq.) was added. Ru 3 (CO) 12(0.639 g, 1.54 mmol, 0.03 eq.), nitrogen was pumped three times and then heated to 105 ° C, and the reaction was continued for 10 h. After the reaction solution was cooled to room temperature, it was filtered with diatomaceous earth. After concentration, it was separated and purified by column chromatography (PE: EA) = 10: 1 to obtain intermediate 3.1 (12.86 g, 59.53% yield). MS: [M+H] + =420.

[0131] Add intermediate 3.1 (12.00 g, 0.028 mol, 1.0 eq.) to the reaction flask, add acetic anhydride (60 mL) to dissolve, and drop 1 drop of concentrated sulfuric acid. Add dilute nitric acid (55 mL) dropwise under ice-salt bath conditions. Control the internal temperature not to exceed 45°C. After the addition is complete, react at room temperature for 1 hour. Pour the reaction solution into ice-cold 30% sodium hydroxide aqueous solution (250 mL), extract twice with ethyl acetate, wash the organic phase with saturated brine, and MgSO 4 After drying and spin drying, intermediate 3.2 (10.42 g, 100% yield) was obtained, which was directly used for the next step reaction.

[0132] Dissolve intermediate 3.2 (10.42 g, 0.028 mol, 1.0 eq.) in DCM, add triethylamine (8.67 g, 0.085 mol, 3.0 eq.), DMAP (0.37 g, 0.0028 mol, 0.1 eq.). Add di-tert-butyl dicarbonate (9.36 g, 0.043 mol, 1.5 eq.) under ice bath conditions. Transfer to room temperature and react for 2 h. After concentrating the reaction solution, separate and purify by column chromatography (PE:EA=4:1) to obtain intermediate 3.3 (6.75 g, 50.8% yield). MS: [M+H] + =465.

[0133] Add DCM (80 mL) and DMF (80 mL) to a reaction bottle containing intermediate 3.3 (6.75 g, 0.0145 mol, 1.0 eq.). Stir and dissolve before adding stannous chloride dihydrate (16.4 g, 0.073 mol, 5.0 eq.). Stir at room temperature for 2 h. Add saturated sodium bicarbonate aqueous solution (1 L) to the reaction solution. Extract twice with ethyl acetate, wash with saturated sodium chloride aqueous solution, MgSO 4 Dry. Spin dry and purify by column chromatography (PE:EA=4:1) to obtain intermediate 3.4 (5.10 g, 80.9% yield). MS: [M+H] + =435.

[0134] To the reaction bottle containing intermediate 3.4 (5.10 g, 0.012 mol, 1.0 eq.), add chloroform (50 mL), acetic anhydride (8.17 g, 0.029 mol, 2.5 eq.), and potassium acetate (0.58 g, 0.006 mol, 0.5 eq.). After heating to 70 °C, add isoamyl nitrite (3.46 g, 0.029 mol, 2.5 eq.) dropwise. React for 1 hour, and add water (50 mL) to the reaction solution. Extract twice with 100 mL*2 of ethyl acetate, wash with saturated sodium chloride aqueous solution, and MgSO 4 Dry. Spin dry and purify by column chromatography (PE:EA=4:1) to obtain intermediate 3.5 (4.20 g, 80.7% yield). MS: [M+H] + =446.

[0135] Add DMF (10 mL) to the reaction bottle containing intermediate 3.5 (1.00 g, 0.0022 mol, 1.0 eq.). Stir and lower the temperature to 0°C. Slowly add NaH (0.108 g, 0.0027 mol, 1.2 eq.). After 0.5 h, add 1,2,3-oxathiozolidine-3-carboxylic acid tert-butyl ester 2,2-dioxide (1.02 g, 0.0045 mol, 2.0 eq.). Naturally warm to room temperature and react for 6 h. Add water to the reaction solution, extract twice with ethyl acetate, wash the organic phase with saturated sodium chloride aqueous solution, and MgSO 4 Drying. Spin drying gave intermediate 3.6 (0.850 g, 64.4% yield). MS: [M+H] + =589.

[0136] Add methanol (10 mL) to the reaction bottle containing intermediate 3.6 (0.850 g, 0.0015 mol, 1.0 eq.), then add hydrochloric acid 1,4-dioxane solution (4 M, 3 mL), heat to 70 ° C, and react for 0.5 h. After the reaction liquid is dried, intermediate 3.7 is obtained, which is directly used in the next step reaction.

[0137] Add methanol (10 mL) to the reaction bottle containing intermediate 3.7, stir to dissolve, add cesium carbonate (1.41 g, 0.0045 mol, 3.0 eq.), heat to 70°C, and react for 2 h. The reaction liquid is spin-dried to obtain intermediate 3.8, which is directly used in the next step.

[0138] Add DCM (10 mL) to the reaction bottle containing intermediate 3.8, stir and dissolve, add triethylamine (0.438 g, 0.0045 mol, 3.0 eq.), add di-tert-butyl dicarbonate (0.472 g, 0.0022 mol, 1.5 eq.) under ice-water bath. Transfer to room temperature and react for 1 h. After the reaction liquid is spin-dried, it is separated and purified by column chromatography (DCM: MeOH = 20: 1) to obtain intermediate 3.9 (0.35 g, 53.1% yield). MS: [M+H] + =457.

[0139] DMF (10 mL) was added to the reaction bottle containing intermediate 3.9 (0.35 g, 0.765 mmol, 1.0 eq.), stirred, and t-BuOK (0.174 g, 1.53 mmol, 2.0 eq.) was added under ice-water bath conditions. After stirring for 20 min, 2-(benzyloxy)-3-(chloromethyl)-6-methyl-4-(methylthio)pyridine (0.256 g, 0.92 mmol, 1.2 eq.) was added. After reacting for 3 h, water (50 mL) was added to the reaction solution, and then extracted with ethyl acetate (50 mL×3). Washed with saturated sodium chloride aqueous solution, MgSO 4 Dry. Spin dry and purify by column chromatography (PE:EA=4:1) to obtain intermediate 3.10 (0.24 g, 43.8% yield) as a yellow solid. MS: [M+H] + =714.

[0140] Intermediate 3.10 (0.24 g, 0.336 mmol, 1.0 eq.) was dissolved in 10 mL of methanol, and 1,4-dioxane hydrochloride (3 mL, 7 M) was added, and the temperature was raised to 70°C for 0.5 h. The reaction solution was dried to obtain intermediate 2.11 (0.51 g, 100% yield).

[0141] The intermediate 3.10 (0.51 g, 0.336 mmol, 1.0 eq.) was dissolved in 10 mL of methanol, and a formaldehyde aqueous solution (1.10 mL, 37%, 10 eq.) was added. After stirring for 15 min, STAB (0.35 g, 1.68 mmol, 5 eq.) was added and stirred for another 15 min. The reaction solution was then spin-dried and purified by column chromatography (DCM: MeOH = 8: 1) to obtain the title compound of Example 3 (0.11 g, 59.5% yield). MS: [M+H] + =552. 1 H NMR (400 MHz, DMSO-d 6)11.71(s,1H),8.04(s,1H),6.15(s,1H),4.73(s,2H),4.07(s,2H),3.51(s,2H),2.65(s,3H),2.41(d,J =7.7Hz,6H),2.32-2.36(m,1H),2.30(s,3H),2.21(s,3H),1.89(s,5H),1.59(s,3H),1.19-1.28(m,4H).

[0142] Intermediate 1.4.1 Methyl (R)-7-bromo-2-((1r, 4S)-4-((tert-butoxycarbonyl)amino)cyclohexyl)-2,4-dimethyl-6-nitrobenzo[d][1,3]dioxine-5-carboxylate and Intermediate 1.4.2 Methyl (S)-7-bromo-2-((1R, 4R)-4-((tert-butoxycarbonyl)amino)cyclohexyl)-2,4-dimethyl-6-nitrobenzo[d][1,3]dioxine-5-carboxylate

[0143]

[0144] Compounds 1.4.1 and 1.4.2 were prepared by chiral separation of intermediate 1.4. The details are as follows:

[0145] Separation equipment: Waters UPC2 analytical SFC

[0146] Column: ChiralCel OJ, 150×4.6mm ID, 3μm

[0147] Mobile phase: A for CO 2 and B for Methanol(0.1% NH 3 H 2 O)

[0148] Gradient: B 10%

[0149] Flow rate: 2.0mL / min

[0150] Wavelength: 220nm

[0151] Compound 1.4.1 retention time 4.22 minutes, [α] = -30.3° (MeOH, c = 1.0 g / 100 mL)

[0152] Compound 1.4.2 retention time 3.70 minutes, [α] = 25.4° (MeOH, c = 1.0 g / 100 mL)

[0153] HPLC equipment: Shimadzu LC-20AD

[0154] MS:[M+H] + =529. 1 H NMR (400MHz, DMSO) δ6.76 (d, J = 7.8Hz, 1H),

[0155] 3.79(s,3H),3.18(s,1H),2.18(s,3H),1.90-1.75(m,5H),1.70(s,3H),1.37(s,9H),1.27-1.09(m,4H).

[0156] Example 4: Synthesis of (R)-10-((1r, 4R)-4-(dimethylamino)cyclohexyl)-8,10-dimethyl-6-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5,6-dihydro-[1,4]diazepine[6,7,1-hi][1,3]dioxa[4,5-e]indol-7(4H)-one

[0157]

[0158] Compound 4 was synthesized by similar steps in Example 1, and intermediate 1.4 was split and replaced with 1.4.1 (2.20 g, 0.0043 mol, 1.0 eq.). MS: [M+H] + =551. 1 H NMR (400 MHz, DMSO-d 6 )δ11.71(s,1H),7.21(d,J=3.1Hz,1H),6.30(d,J=3.0Hz,1H),6.14(s,1H),4.72(s,2H),4.06(s,2H),3.51(s,2H),2 .68(s,1H),2.54(s,6H),2.42(s,3H),2.40(s,3H),2.21(s,3H),2.08-1.76(m,5H),1.59(s,3H),1.36-1.20(m,4H).

[0159] Example 5: Synthesis of (S)-10-((1r,4S)-4-(dimethylamino)cyclohexyl)-8,10-dimethyl-6-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5,6-dihydro-[1,4]diazepine[6,7,1-hi][1,3]dioxa[4,5-e]indol-7(4H)-one

[0160]

[0161] Compound 5 was synthesized by similar steps in Example 1, and intermediate 1.4 was split and replaced with 1.4.2 (2.20 g, 0.0043 mol, 1.0 eq.). MS: [M+H] + =551. 1 H NMR (400 MHz, DMSO-d 6 )11.70(s,1H),7.21(s,1H),6.30(s,1H),6.14(s,1H),4.73(s,2H),4.07(s,2H),3.51(s,2H),2.65(s,3H),2. 41(d,J=7.7Hz,6H),2.32-2.36(m,1H),2.30(s,3H),2.21(s,3H),1.89(s,5H),1.59(s,3H),1.29-1.19(m,4H).

[0162] Example 6: Synthesis of (4R, 10R)-10-((1r, 4R)-4-(dimethylamino)cyclohexyl)-4,8,10-trimethyl-6-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5,6-dihydro-[1,4]diazepine[6,7,1-hi][1,3]dioxa[4,5-e]indol-7(4H)-one

[0163]

[0164] Compound 6 was synthesized by similar steps in Example 4, except that 1,2,3-oxathiazolidine-3-carboxylic acid tert-butyl ester 2,2-dioxide was replaced with (S)-5-methyl-1,2,3-oxathiazolidine-3-carboxylic acid tert-butyl ester-2,2-dioxide. MS: [M+H] + =565. 1 H NMR (400 MHz, DMSO-d 6 )δ11.65(s,1H),7.36-7.26(m,1H),6.29(s,1H),6.13(s,1H),5.12(s,2H),4.53(s,2H),4.23(s,1H),3.46(s,3H),2 .68(s,1H),2.51(s,3H),2.44(s,3H),2.39(s,3H),2.21(s,3H),1.95(m,5H),1.60(s,3H),1.43(s,3H),1.32(m,4H).

[0165] Example 7: Synthesis of (4S,10R)-10-((1r,4R)-4-(dimethylamino)cyclohexyl)-4,8,10-trimethyl-6-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5,6-dihydro-[1,4]diazepine[6,7,1-hi][1,3]dioxa[4,5-e]indol-7(4H)-one

[0166]

[0167] Compound 7 was synthesized by similar steps in Example 6, except that (R)-4-methyl-1,2,3-oxathiozolidine-3-carboxylic acid tert-butyl ester 2,2-dioxide was replaced with (R)-5-methyl-1,2,3-oxathiozolidine-3-carboxylic acid tert-butyl ester 2,2-dioxide. MS: [M+H] + =565. 1 H NMR (400 MHz, DMSO-d 6 )δ11.67(s,1H),7.31(s,1H),6.30(s,1H),6.13(s,1H),5.11(s,1H),4.51(d,J=15.8Hz,2H),3.50-3.43(m,2H),2.68(s, 1H),2.63(s,6H),2.44(s,3H),2.39(s,3H),2.21(s,3H),2.09-1.87(m,5H),1.61(s,3H),1.44(s,3H),1.39-1.20(m,4H).

[0168] Example 8: Synthesis of (10R)-10-((1r, 4R)-4-(dimethylamino)cyclohexyl)-5,8,10-trimethyl-6-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5,6-dihydro-[1,4]diazepine[6,7,1-hi][1,3]dioxa[4,5-e]indol-7(4H)-one

[0169]

[0170] Compound 8 was synthesized by similar steps in Example 6, except that (R)-4-methyl-1,2,3-oxathiozolidine-3-carboxylic acid tert-butyl ester 2,2-dioxide was replaced with 4-methyl-1,2,3-oxathiozolidine-3-carboxylic acid tert-butyl ester 2,2-dioxide. MS: [M+H] + =565. 1H NMR (400MHz, DMSO) δ11.69(s,1H),7.18(d,J=2.9Hz,1H),6.30(d,J=3.0Hz,1H),6.13(s,1 H),4.93(d,J=13.8Hz,1H),4.54(d,J=13.7Hz,1H),4.31(dd,J=13.5,4.5Hz,1H),4.15(d, J=13.5Hz,1H),3.90-3.80(m,1H),2.52(s,3H),2.47(s,3H),2.42(s,6H),2.38-2.25(m,1 H), 2.20 (s, 3H), 2.06-1.83 (m, 5H), 1.60 (s, 3H), 1.42-1.20 (m, 4H), 0.59 (d, J = 7.0Hz, 3H).

[0171] Example 9: Synthesis of (R)-10-((1r,4R)-4-(dimethylamino)cyclohexyl)-6-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-8,10-dimethyl-5,6-dihydro-[1,4]diazepine[6,7,1-hi][1,3]dioxa[4,5-e]indol-7(4H)-one

[0172]

[0173] Compound 9 was synthesized by similar steps in Example 4, except that 2-(benzyloxy)-3-(chloromethyl)-6-methyl-4-(methylthio)pyridine was replaced by 2-(benzyloxy)-3-(chloromethyl)-4-methoxy-6-methylpyridine. MS: [M+H] + =535. 1 HNMR (400 MHz, DMSO-d 6 )11.58(s,1H),7.21(s,1H),6.29(s,1H),6.14(s,1H),5.15(s,2H),4.33(s,2H),3.80(s,3H),3.51(s,2H),2.40( d,J=8.0Hz,6H),2.32-2.36(m,1H),2.30(s,3H),2.21(s,3H),1.95-1.79(m,5H),1.59(s,3H),1.29-1.19(m,4H).

[0174] Example 10: Synthesis of (S)-10-((1r,4S)-4-(dimethylamino)cyclohexyl)-6-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-8,10-dimethyl-5,6-dihydro-[1,4]diazepine[6,7,1-hi][1,3]dioxa[4,5-e]indol-7(4H)-one

[0175]

[0176] Compound 10 was synthesized using similar steps as in Example 5, except that 2-(benzyloxy)-3-(chloromethyl)-6-methyl-4-(methylthio)pyridine was replaced with 2-(benzyloxy)-3-(chloromethyl)-4-methoxy-6-methylpyridine. MS: [M+H] + =535. 1 H NMR (400 MHz, DMSO-d 6 )11.58(s,1H),7.21(s,1H),6.29(s,1H),6.14(s,1H),4.56(s,2H),4.33(s,2H),3.79(s,3H),3.51(s,2H),2 .40(s,6H),2.32-2.36(m,1H),2.30(s,3H),2.21(s,3H),1.95-1.79(m,5H),1.59(s,3H),1.29-1.19(m,4H).

[0177] Example 11: Synthesis of (R)-6-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-10-((1r,4R)-4-(dimethylamino)cyclohexyl)-8,10-dimethyl-5,6-dihydro-[1,4]diazepine[6,7,1-hi][1,3]dioxa[4,5-e]indol-7(4H)-one

[0178]

[0179] Compound 11 was synthesized using similar steps as in Example 4, except that 2-(benzyloxy)-3-(chloromethyl)-6-methyl-4-(methylthio)pyridine was replaced with 2-(benzyloxy)-3-(chloromethyl)-4,6-dimethylpyridine. MS: [M+H] + =519. 1 HNMR (400 MHz, DMSO-d 6)11.66(s,1H),7.23(s,1H),6.31(s,1H),5.94(s,1H),4.74(s,2H),4.13(s,2H),3.63(s,2H),2.80(s,1H ),2.38(s,3H),2.19(s,3H),2.15(s,3H),1.95-1.80(m,5H),1.60(s,3H),1.41-1.24(m,4H),1.11(s,6H).

[0180] Synthesis of Intermediate 3.5.1 Methyl (R)-2-((1r, 4R)-4-((tert-butyloxycarbonyl)amino)cyclohexyl)-2,4-dimethyl-6H-[1,3]dioxacyclo[4,5-e]indazole-5-carboxylate and Intermediate 3.5.2 Methyl (S)-2-((1r, 4S)-4-((tert-butyloxycarbonyl)amino)cyclohexyl)-2,4-dimethyl-6H-[1,3]dioxacyclo[4,5-e]indazole-5-carboxylate

[0181]

[0182] Compounds 3.5.1 and 3.5.2 were prepared by chiral separation of intermediate 3.5. The details are as follows:

[0183] Separation equipment: Waters UPC2 analytical SFC

[0184] Column: ChiralCel OJ, 150×4.6mm ID, 3μm

[0185] Mobile phase: A for CO 2 and B for Methanol(0.1% NH 3 H 2 O)

[0186] Gradient: B 40%

[0187] Flow rate: 2.0mL / min

[0188] Wavelength: 220nm

[0189] Compound 3.5.1 retention time 2.72 minutes, [α] = 38.0° (MeOH, c = 1.0 g / 100 mL)

[0190] Compound 3.5.2 retention time 4.39 minutes, [α] = -29.1° (MeOH, c = 1.0 g / 100 mL)

[0191] MS:[M+H] + =446.1 H NMR (400MHz, DMSO) δ12.91 (s, 1H), 8.11 (d, J=

[0192] 1.3Hz,1H),6.75(d,J=7.9Hz,1H),3.90(s,3H),3.23-3.11(m,1H),2.54 (s,3H),1.94-1.77(m,5H),1.64(s,3H),1.36(s,9H),1.24-1.05(m,4H).

[0193] Example 12: Synthesis of (R)-10-((1r,4R)-4-(dimethylamino)cyclohexyl)-8,10-dimethyl-6-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5,6-dihydro-[1,4]diazepine[6,7,1-hi][1,3]dioxa[4,5-e]indazol-7(4H)-one

[0194]

[0195] Compound 12 was synthesized by similar steps in Example 3, and intermediate 3.5 was split and replaced with 3.5.1 (2.20 g, 0.0043 mol, 1.0 eq.). MS: [M+H] + =552. 1 H NMR(400MHz,DMSO)δ11.69(s,1H),8.03(s,1H),6.15(s,1H),4.75(s,2H),4.26(s,2H),3.60(s,2H),2.49 (s,3H),2.42(s,3H),2.23(s,3H),2.17(s,6H),2.15-2.08(m,1H),1.89(m,5H),1.64(s,3H),1.21(m,4H).

[0196] Example 13: Synthesis of (S)-10-((1r,4S)-4-(dimethylamino)cyclohexyl)-8,10-dimethyl-6-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5,6-dihydro-[1,4]diazepine[6,7,1-hi][1,3]dioxa[4,5-e]indazol-7(4H)-one

[0197]

[0198] Compound 13 was synthesized by similar steps in Example 12, except that intermediate 3.5.1 was replaced with 3.5.2 (2.20 g, 0.0043 mol, 1.0 eq.). MS: [M+H] + =552. 1 H NMR(400MHz,DMSO)δ11.71(s,1H),8.04(s,1H),6.15(s,1H),4.75(s,2H),4.26(s,2H),3.59(s,2H),2.52 (s,3H),2.49(s,6H),2.42(s,3H),2.34(s,1H),2.23(s,3H),1.98m,5H),1.65(s,3H),1.33-1.14(m,4H).

[0199] Example 14: Synthesis of (4R,10R)-10-((1r,4R)-4-(dimethylamino)cyclohexyl)-4,8,10-trimethyl-6-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5,6-dihydro-[1,4]diazepine[6,7,1-hi][1,3]dioxa[4,5-e]indazol-7(4H)-one

[0200]

[0201] Example 14 was synthesized by similar steps to Example 12, except that 1,2,3-oxathiozolidine-3-carboxylic acid tert-butyl ester 2,2-dioxide was replaced with (S)-5-methyl-1,2,3-oxathiozolidine-3-carboxylic acid tert-butyl ester 2,2-dioxide. MS: [M+H] + =566. 1 H NMR (400MHz, DMSO) δ11.70(s,1H),8.03(s,1H),6.13(s,1H),5.01(s,1H),4.60(d,J=13.9Hz,2H),3.68-3.45(m,2H),2.46(s,3 H),2.43(s,3H),2.23(s,3H),2.17(s,6H),2.14-2.08(m,1H),2.02-1.75(m,5H),1.63(s,3H),1.42(s,3H),1.25-1.14(m,4H).

[0202] Example 15: Synthesis of (4S,10R)-10-((1r,4R)-4-(dimethylamino)cyclohexyl)-4,8,10-trimethyl-6-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5,6-dihydro-[1,4]diazepin[6,7,1-hi][1,3]dioxa[4,5-e]indazol-7(4H)-one

[0203]

[0204] Example 15 was synthesized by similar steps to Example 12, except that 1,2,3-oxathiozolidine-3-carboxylic acid tert-butyl ester 2,2-dioxide was replaced with (R)-5-methyl-1,2,3-oxathiozolidine-3-carboxylic acid tert-butyl ester 2,2-dioxide. MS: [M+H] + =566. 1 H NMR (400MHz, DMSO) δ11.70(s,1H),8.03(s,1H),6.14(s,1H),5.02(s,1H),4.59(m,2H),3.55(s,2H),2.46(s,3H),2.43( s,3H),2.33(s,1H),2.27(s,6H),2.22(s,3H),1.91(d,J=22.4Hz,5H),1.64(s,3H),1.41(d,J=14.4Hz,3H),1.23(s,4H).

[0205] Example 16: Synthesis of (R)-1-chloro-10-((1r,4R)-4-(dimethylamino)cyclohexyl)-8,10-dimethyl-6-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5,6-dihydro-[1,4]diazepine[6,7,1-hi][1,3]dioxa[4,5-e]indol-7(4H)-one

[0206]

[0207] Intermediate 4.4 (0.81 g, 1.8 mmol, 1.0 eq.) was dissolved in dichloromethane, and N-chlorosuccinimide (0.36 g, 2.7 mmol, 1.5 eq.) was added, and stirred at room temperature overnight. The reaction solution was then spin-dried and purified by column chromatography to obtain intermediate 16.1 (0.81 g, 92.0% yield). MS: [M+H] + =479.

[0208] Compound 16 was prepared by a similar synthetic method to compound 4, with intermediate 16.1 replacing intermediate 4.4. MS: [M+H] +=586. 1 H NMR (400 MHz, DMSO-d 6 )δ11.72(s,1H),7.39(s,1H),6.14(s,1H),4.71(s,3H),4.03(s,2H),3.50(s,2H),2.68(s,1H),2.54(s,2H ),2.50(s,3H),2.43(s,3H),2.39(s,3H),2.21(s,3H),2.05-1.87(m,5H),1.63(s,3H),1.34-1.19(m,4H).

[0209] Example 17: Synthesis of (4R, 10R)-10-((1r, 4R)-4-(dimethylamino)cyclohexyl)-6-((4-methoxy-6-methyl-2-oxy-1,2-dihydropyridin-3-yl)methyl)-4,8,10-trimethyl-5,6-dihydro-[1,4]diazepine[6,7,1-hi][1,3]dioxa[4,5-e]indol-7(4H)-one

[0210]

[0211] Compound 17 was synthesized by similar steps in Example 6, except that 2-(benzyloxy)-3-(chloromethyl)-6-methyl-4-(methylthio)pyridine was replaced by 2-(benzyloxy)-3-(chloromethyl)-4-methoxy-6-methylpyridine. MS: [M+H] + =549.24. 1 H NMR (400 MHz, DMSO-d 6 )δ:11.53(s,1H),7.30(s,1H),6.29(d,1H),6.14(s,1H),5.15(s,2H),4.33(s,2H),3.80(s,3H),3.5 1-3.79(m,2H),2.35(m,7H),2.21(s,3H),1.58(m,3H),1.90(m,4H),1.85(s,3H),1.39-1.23(m,7H).

[0212] Example 18: Synthesis of (4S,10R)-10-((1r,4R)-4-(dimethylamino)cyclohexyl)-6-((4-methoxy-6-methyl-2-oxy-1,2-dihydropyridin-3-yl)methyl)-4,8,10-trimethyl-5,6-dihydro-[1,4]diazepine[6,7,1-hi][1,3]dioxa[4,5-e]indol-7(4H)-one

[0213]

[0214] Compound 18 was synthesized by similar steps in Example 7, except that 2-(benzyloxy)-3-(chloromethyl)-6-methyl-4-(methylthio)pyridine was replaced by 2-(benzyloxy)-3-(chloromethyl)-4-methoxy-6-methylpyridine. MS: [M+H] + =549.27. 1 H NMR (400 MHz, DMSO-d 6 )δ:11.53(s,1H),7.30(s,1H),6.29(d,1H),6.13(s,1H),5.09(brs,2H),4.23(m,2H),3.80(s, 3H),2.60(m,2H),2.37(m,6H),2.21(s,3H),1.91-1.86(m,8H),1.58(s,3H),1.38-1.25(m,7H).

[0215] Example 19: Synthesis of (4R, 10R)-6-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-10-((1r, 4R)-4-(dimethylamino)cyclohexyl)-4,8,10-trimethyl-5,6-dihydro-[1,4]diazepine[6,7,1-hi][1,3]dioxa[4,5-e]indol-7(4H)-one

[0216]

[0217] Compound 19 was synthesized by similar steps in Example 6, except that 2-(benzyloxy)-3-(chloromethyl)-6-methyl-4-(methylthio)pyridine was replaced by 2-(benzyloxy)-3-(chloromethyl)-4,6-dimethylpyridine. MS: [M+H] + =533.36. 1 H NMR (400 MHz, DMSO-d 6 )δ:11.60(s,1H),7.31(s,1H),6.30(s,1H),5.92(s,1H),5.06(s,1H),4.47(s,2H),3.69(s,1H),3.59(s,1H),2.51(s,2H), 2.35(s,3H),2.39(s,2H),2.22(s,6H),2.15(s,3H),1.92-1.87(m,5H),1.58(s,3H),1.44-1.43(m,3H),1.20-1.18(m,4H).

[0218] Example 20: Synthesis of ((5R,10R)-10-((1r,4R)-4-(dimethylamino)cyclohexyl)-5,8,10-trimethyl-6-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5,6-dihydro-[1,4]diazepine[6,7,1-hi][1,3]dioxa[4,5-e]indol-7(4H)-one

[0219]

[0220] Compound 20 was synthesized by similar steps in Example 4, except that 1,2,3-oxathiozolidine-3-carboxylic acid tert-butyl ester 2,2-dioxide was replaced with (R)-4-methyl-1,2,3-oxathiozolidine-3-carboxylic acid tert-butyl ester-2,2-dioxide. MS: [M+H] + =565.46. 1 H NMR (400 MHz, DMSO-d 6 )δ:11.69(s,1H),7.18(d,J=2.9Hz,1H),6.30(d,J=3.0Hz,1H),6.13(s,1H),4.93(d, J=13.8Hz,1H),4.54(d,J=13.7Hz,1H),4.31(dd,J=13.5,4.5Hz,1H),4.15(d,J=13.5H z,1H),3.90-3.80(m,1H),2.52(s,3H),2.47(s,3H),2.42(s,6H),2.38-2.25(m,1H),2 .20(s,3H),2.06-1.83(m,5H),1.60(s,3H),1.42-1.20(m,4H),0.59(d,J=7.0Hz,3H).

[0221] Example 21: Synthesis of (S)-8-chloro-10-((1r,4S)-4-(dimethylamino)cyclohexyl)-10-methyl-6-((6-methyl-4-(methylthio)-2-oxy-1,2-dihydropyridin-3-yl)methyl)-5,6-dihydro-[1,4]diazepine[6,7,1-hi][1,3]dioxa[4,5-e]indol-7(4H)-one

[0222]

[0223] Compound 21 was synthesized by similar steps in Example 2, and intermediate 1.4 was split and replaced with 1.4.1 to obtain the compound. MS: [M+H] + =571.14. 1 H NMR (400 MHz, DMSO-d6 )δ:11.72(s,1H),7.33(s,1H),6.38(d,1H),6.15(s,1H),4.70(s,2H),4.08(s,2H),3.5 5(s,2H),2.51(s,3H),2.43(s,3H),2.22(m,8H),1.92(m,4H),1.64(m,3H),1.23(m,4H).

[0224] Example 22: Synthesis of (4R, 10S)-8-chloro-10-((1r, 4S)-4-(dimethylamino)cyclohexyl)-4,10-dimethyl-6-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5,6-dihydro-[1,4]diazepine[6,7,1-hi][1,3]dioxa[4,5-e]indol-7(4H)-one

[0225]

[0226] Compound 22 was synthesized by similar steps in Example 21, except that 1,2,3-oxathiozolidine-3-carboxylic acid tert-butyl ester 2,2-dioxide was replaced with (S)-5-methyl-1,2,3-oxathiozolidine-3-carboxylic acid tert-butyl ester-2,2-dioxide. MS: [M+H] + =585.16. 1 H NMR (400 MHz, DMSO-d 6 )δ:11.68(s,1H),7.43(d,1H),6.28(d,1H),6.13(s,1H),5.05(s,2H),4.52(s,2H),3.50(s ,2H),2.51-2.50(m,3H),2.49(s,3H),2.20(m,7H),1.91(m,4H),1.62(m,3H),1.32(m,7H).

[0227] Example 23: Synthesis of (R)-8-chloro-10-((1r,4R)-4-(dimethylamino)cyclohexyl)-10-methyl-6-((6-methyl-4-(methylthio)-2-oxy-1,2-dihydropyridin-3-yl)methyl)-5,6-dihydro-[1,4]diazepine[6,7,1-hi][1,3]dioxa[4,5-e]indol-7(4H)-one

[0228]

[0229] Compound 23 was synthesized by similar steps in Example 2, and the intermediate 1.4 was split and replaced with 1.4.2 to obtain the compound. MS: [M+H]+ =572.23. 1 H NMR (400 MHz, DMSO-d 6 )δ:11.73(s,1H),7.35(d,J=3.3Hz,1H),6.38(d,J=3.3Hz,1H),6.15(s,1H),4.73(d,J=17.8Hz,2H),4.56(s,2H) ,3.55(s,2H),2.63(s,3H),2.43(s,3H),2.34(s,1H),2.22(s,7H),2.01(m,4H),1.62(m,3H),1.38(m,7.5Hz,4H).

[0230] Example 24: Synthesis of (4R, 10S)-8-chloro-6-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-10-((1r, 4S)-4-(dimethylamino)cyclohexyl)-4,10-dimethyl-5,6-dihydro-[1,4]diaza[6,7,1-hi][1,3]dioxin[4,5-e]indol-7(4H)-one

[0231]

[0232] Compound 24 was synthesized by similar steps in Example 22, except that 2-(benzyloxy)-3-(chloromethyl)-6-methyl-4-(methylthio)pyridine was replaced with 2-(benzyloxy)-3-(chloromethyl)-4,6-dimethylpyridine. MS: [M+H] + =572.42. 1 H NMR (400 MHz, DMSO-d 6 )δ:11.65(s,1H),7.54(s,1H),6.38(d,1H),5.93(s,1H),5.08(s,1H),4.52(m,2H),3.74(s,1H),3.35(s ,2H),2.51-2.50(m,3H),2.21(s,2H),2.06(m,6H),1.85(m,5H),1.63(m,3H),1.47(m,3H),1.14(m,5H).

[0233] Experimental Example 1

[0234] PRC2 / EZH 2HTRF enzyme inhibition assay

[0235] PRC2 complex was purchased from Carna Biosciences (Japan), Histone H3(21-44)-GK (biotin), Streptavidin-XL665 and Mab Anti histone H3K27 Me1-Eu (K) were purchased from Cisbio (France).

[0236] SAM (30 mM), DTT (1 M), 10% BAS, Tris-HCl (50 mM), NaCl (50 mM), 10% Tween and dimethyl sulfoxide (DMSO) were purchased from Sigma, and 384-well white plates were purchased from CORNING (USA).

[0237] The assay buffer used in the experiment consists of 50mM Tris-HCl, 50mM NaCl, 1mM DTT, 0.01% Tween, and 0.1% BSA. The assay buffer was used to prepare a 5% DMSO compound, PRC2 enzyme, and Histone H3(21-44)-GK mixed solution. After the preparation, 2μL of 5% DMSO compound and 4μL of PRC2 mixed solution were added to the OptiPlate-384 White well plate, covered with a membrane at 800 rpm for 1min, incubated at room temperature for 0.5h, and 4μL of Histone H3(21-44)-GK(biotin) / SAM was added and covered with a membrane at 800 rpm for 1min, and incubated at room temperature for 2h. The final concentrations of PRC2, Histone H3(21-44)-GK(biotin), SAM, and DMSO were 1ng / μL, 5μM, 15μM, and 1%, respectively. Then, 5 μL of detection antibody Mab Anti histoneH3K27 Me1-Eu(K) and 5 μL of Streptavidin-XL665 were added and incubated at room temperature for 2 h. The plate was read on a SPARK multifunctional microplate reader from TECAN (Switzerland) with an excitation wavelength of 320 nm and an emission wavelength of 665 nm. The compound IC was determined using a sigmoidal dose-response model (variable slope, four parameters) in Prism 7 (LaJolla, CA). 50 value.

[0238] Cell proliferation inhibition assay

[0239] Karpas422 cells were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai); RPMI1640 medium, penicillin-streptomycin double antibody and 0.5% trypsin (10X) were purchased from ThermoFisher (Waltham, MA, USA). Certified fetal bovine serum (FBS) was purchased from Biological Industries (Israel). Corning 96-well cell culture plates were purchased from CORNING (USA). CountingKit-8 detection kit was purchased from Beyotime (China).

[0240] In order to evaluate the inhibitory effect of the synthesized compounds on the proliferation of human large cell lymphoma SU-DHL-10 and human B cell non-Hodgkin's lymphoma Karpas422 cells, the exponentially growing SU-DHL-10 and Karpas422 cells were inoculated in RPMI1640 medium containing 20% ​​bovine serum and 1% penicillin-streptomycin double antibody at a density of 1000 cells / mL in 96-well plates, with 100 μL per well, and placed at 37°C and 5% CO 2 Incubate overnight in a 5% CO incubator. Dilute the compound in DMSO to an initial concentration of 2 mM, 3-fold dilution, 12 concentrations. Add 1 μL of DMSO solution from the compound stock plate to 99 μL of cell culture medium, the final maximum concentration of the compound in the assay is 10 μM, and the final concentration of DMSO is (0.5%). Add 100 μL of compound solution in culture medium to each well of the SU-DHL-10 and Karpas422 cell plates. After adding the compound solution, place the 96-well plate at 37°C, 5% CO 2 Incubate in an incubator for 8 days. Cell viability was determined using the Counting Kit-8 assay kit by quantifying the amount of formazan produced in the cell culture, which is proportional to the number of viable cells. After 2 hours of incubation, the reading was performed using the TECAN SPARK multifunctional microplate reader under the chemiluminescence program. The S-shaped dose-response model (variable slope, four parameters) was used in Prism 7 (LaJolla, CA) to determine the concentration of the compound that inhibited cell viability by 50% (IC 50 value).

[0241] The results of the EZH2 enzyme inhibition assay and cell proliferation inhibition assay of the representative compounds described herein are shown in Table 1.

[0242] Table 1

[0243]

[0244]

[0245] From the test results in Table 1, most of these compounds have excellent EZH2 inhibitory activity, and some of them have better EZH2 inhibitory activity than the existing positive reference, especially compound 4, compound 6, compound 7, compound 12 and compound 16. At the same time, these compounds also showed obvious proliferation and transplantation activity, which has obvious advantages over the marketed drug Tazemetostat.

[0246] Experimental Example 2 In vitro liver microsome stability test

[0247] Human liver microsomes were from Corning, and ICR / CD-1 rat liver microsomes (male) were also from Corning, and were stored in a -80°C refrigerator. Sodium dihydrogen phosphate, potassium dihydrogen phosphate, and NADPH were purchased from Sigma.

[0248] Prepare a high concentration stock solution of the test substance with DMSO, dilute it with DMSO to a 200μM working solution before use, and the final concentration of the test substance is 1μM. First weigh 7.098g of disodium hydrogen phosphate, add 500mL of pure water and ultrasonically dissolve it as solution A. Weigh 3.400g of potassium dihydrogen phosphate, add 250mL of pure water and ultrasonically dissolve it as solution B. Add solution B to solution A until the pH is 7.4. Before the experiment, weigh an appropriate amount of NADPH and prepare a working solution with a concentration of 10mM using phosphate solution. Transfer 25μL of NADPH or phosphate buffer to the above incubation system and add 2μL of 200μM test compound. For samples with NADPH, prepare two parallels; for samples with negative NADPH, prepare one parallel. Take 30μL of suspension at 0.5, 5, 15, 30 and 60 minutes respectively. Add 180 μL of acetonitrile containing internal standard to terminate the reaction and vortex for 10 minutes. Then centrifuge at 3220g for 20 minutes to precipitate the protein. Place the plate in a 4°C refrigerator for 30 minutes, and then centrifuge again at 3220g for 20 minutes. Transfer 100 μL of supernatant to the sample plate, add 100 μL of pure water to mix, and use for UPLC-MS / MS analysis. All data calculations are performed using Microsoft Excel software. Peak areas are detected by extracting ion spectra. The in vitro half-life (t 1 / 2 ), and calculate the clearance rate.

[0249] The results of liver microsomal stability experiments of representative compounds described herein are shown in Table 2.

[0250] Table 2

[0251]

[0252]

[0253] From the test results in Table 2, most of these compounds have excellent in vitro liver microsome stability. At the same time, the in vitro liver microsome stability of some of the compounds has better results than the existing positive references, especially compound 3, compound 4, compound 6, compound 7, compound 9, compound 11, compound 12 and compound 19.

Claims

1. A compound represented by the following formula (I), or a pharmaceutically acceptable salt thereof: ; (I) in, R1 is selected from halogen or C1-C6 alkyl; R2 is selected from hydrogen or halogen; R3 is selected from hydrogen or C1-C6 alkyl; L is selected from N; U is selected from C or N; V, T are selected from C; Y is selected from C1-C6 alkyl; X is selected from C1-C6 alkyl, C1-C6 alkoxy or -S-R4, R4 is C1-C6 alkyl; Z is a cyclohexyl group, wherein the para position is substituted with a -NRaRb group; Ra and Rb are each independently selected from C1-C6 alkyl or halogenated C1-C6 alkyl; m and n are each independently 0 or 1; n' is 1; and Represents a double bond.

2. The compound according to claim 1, characterized in that The formula (I) is formula (Ia): ; (Ia) Wherein, R1 is selected from halogen or C1-C6 alkyl; R2 is selected from hydrogen or halogen; R3 is selected from hydrogen or C1-C6 alkyl; L is selected from N; U is selected from C or N; V, T are selected from C; Y is selected from C1-C6 alkyl; X is selected from C1-C6 alkyl, C1-C6 alkoxy or -S-R4, R4 is C1-C6 alkyl; m and n are each independently 0 or 1; n' is 1; and Represents a double bond.

3. The compound according to claim 1, characterized in that The formula (I) is formula (Ic): ; (Ic) Wherein, R1 is selected from halogen or C1-C6 alkyl; R2 is selected from hydrogen or halogen; R3 is selected from hydrogen or C1-C6 alkyl; U is selected from C or N; V is selected from C; X is selected from C1-C6 alkyl, C1-C6 alkoxy or -S-R4, R4 is C1-C6 alkyl; m and n are each independently 0 or 1; n' is 1; and Represents a double bond.

4. The compound according to claim 1, characterized in that Formula (I) is selected from: , , , , , , , , , , , , , , , , , , , , , , or .

5. A pharmaceutical composition, characterized in that The invention comprises a therapeutically effective amount of the compound according to claim 1, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier or excipient.

6. A use of a compound according to any one of claims 1 to 4 or a pharmaceutically acceptable salt thereof, characterized in that: Used for preparing drugs for treating EZH2-mediated diseases.

7. The use according to claim 6, characterized in that The disease is cancer.

8. The use according to claim 7, characterized in that The cancer is lung cancer, stomach cancer, liver cancer, breast cancer, nasopharyngeal cancer, pancreatic cancer, ovarian cancer, cervical cancer, colorectal cancer, glioma, melanoma, prostate cancer, kidney cancer, esophageal cancer, mesothelioma, head and neck cancer, bladder cancer, salivary gland cancer, leukemia or lymphoma.